Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 5Withdrawn 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Genitourinary 1

Conditions

Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 5Cisplatin 5Gemcitabine 4trametinib 2repotrectinib 2pembrolizumab 2enzalutamide 2atezolizumab 2Surveys and Questionnaires 2SS1(dsFv)PE38 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiosurgery 2Paclitaxel 2Nivolumab 2Interviews as Topic 2Docetaxel 2Cetuximab 2Carboplatin 2vinflunine 1veliparib 1vadimezan 1toripalimab 1talazoparib 1sintilimab 1reolysin 1pixantrone 1pertuzumab 1peginterferon alfa-2a 1palbociclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × vadimezan × Tumor-Agnostic × Clear all
NCT01031212 2013-05-13

ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors

University of California, San Francisco

Phase 1 Withdrawn
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡